Intravitreal injection of Conbercept combined with 532-laser retinal photocoagulation for retinal vein occlusion
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [19]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    AIM: To estimate the efficacy and safety of intravitreal injections of 0.5mg conbercept combined with 532-laser retinal photocoagulation for retinal vein occlusion(RVO).

    METHODS: Totally 122 cases(122 eyes)checked in hospital for RVO were randomly divided into two groups by using the random number list during May 2015 to March 2016. The research group with 58 cases(58 eyes)comprised of 24 cases(24 eyes)diagnosed as central retinal vein occlusion and 34 cases(34 eyes)diagnosed as branch retinal vein occlusion. The control group with 64 cases(64 eyes)comprised of 26 cases(26 eyes)diagnosed as central retinal vein occlusion and 38 cases(38 eyes)diagnosed as branch retinal vein occlusion. All the cases were treated with intravitreal conbercept injections while the research group combined with treatment of received 532-laser retinal photocoagulation pre-injection. Optical coherence tomography(OCT)was adapted pre and 1,3 and 6mo after intravitreal injection. The best corrected visual acuity(BCVA), thickness of macular central concave and retinal pigment epithelium uplift area were compared between the two groups.

    RESULTS: BCVA of all cases were increased 1, 3 and 6mo after treatment, and the difference had statistical significance(P<0.05). The research group had a better improvement of BCVA than control group, and there were significant differences between the two groups 3, 6mo after treatment but 1mo. Thickness of macular central concave and retinal pigment epithelium uplift area of two groups were decreased 1, 3 and 6mo after treatment, the difference had statistical significance(P<0.05). The research group had a bigger decrease value than the control group as for thickness of macular central concave and retinal pigment epithelium uplift area, there were significant differences between two groups 3, 6mo after treatment but 1mo. No adverse events occurred during the treatment.

    CONCLUSION: Intraviteal conbercept injection can increase the visual acuity and decrease both the thickness of macular central concave and retinal pigment epithelium uplift area of patients with retinal vein occlusion. Combined with 532-laser retinal photocoagulation will achieve better outcome than intravitreal injection only.

    Reference
    1 Rouvas A, Petrou P,Ntouraki A,et al.Intravitreal ranibizumab(Lucentis)for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Retina 2010; 30(6):893-902
    2 张菁,蔡小军,陈晓敏,等.玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察.中华眼底病杂志2015; 31(1):22-26
    3 张雷鸣,邢立臣,丰亚丽,等.玻璃体腔注射抗VEGF康柏西普联合激光治疗糖尿病黄斑水肿疗效观察.齐齐哈尔医学院学报2016; 37(8):994-996
    4 McIntosh RL,Rogers SL,Lim L,et al.Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117(6):1113-1123
    5 Rogers SL,McIntosh RL,Lim L,et al.Natural history of branch retinal vein occlusion:an evidence-based systematic review. Ophthalmology 2010; 117(6):1094-1101
    6 Noma H, Funatsu H, Mimura T, et al.Vascular endothelial growth factor receptor-2 in macular oedema with retinal vein occlusion. Ophthalmic Res 2012; 48(1):56-58
    7 Deschler EK, Sun JK, Silva PS.Side-effects and complications of laser treatment in diabetic retinal disease. Semin Ophthalmol 2014; 29(5/6):290-300
    8 Chen CH, Chen YH, Wu PC,et al. Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Med J 2010; 33(4):424-435
    9 Feng J, Zhao T, Zhang Y, et al. Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion. PLoS One 2013; 8(7):e68149
    10 Yu DC,Lee JS,Yoo JY,et al.Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects. Mol Ther 2012; 20(5):938-947
    11 Wang Q,Li T,Wu Z,et al.Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. PLoS One 2013; 8(8):e70544
    12 Wu Z,Zhou P,Li X,et al.Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling. PLoS One 2013; 8(3):e57642
    13Li X,Xu G,Wang Y,et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study:AURORA study. Ophthalmology 2014; 121(9):1740-1747
    14 Zhang M,Yu D,Yang C,et al.The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009; 26(1):204-210
    15 Inoue Y,Shimazawa M, Nakamura S, et al, Protective effects of placental growth factor on retinal neuronal cell damage. J Neurosci Res 2014; 92(3):329-337
    16 Sayman Muslubas IB,Kandemir B, Aydin Oral AY, et al.Long-term vision-threatening complications of phakic intraocular lens implantation for high myopia. Int J Ophthalmol 2014; 7(2):376-380
    17 Roy R,Das MK,Pal BP, et al. Authors'reply:Comment to course of diabetic retinopathy before and after renal transplantation. Indian J Ophthalmol 2014; 62(8):897-898
    18 邢凯,亢泽峰.玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析.山东大学耳鼻喉眼学报2016; 30(1):80-82
    19 Zhang M,Zhang J,Yan M,et al.A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy,for exudative age-related macular degeneration. Ophthalmology 2011; 118(4):672-678
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Qin Li, Shao-Wei Zhang, Die-Nian Zhang. ,/et al.Intravitreal injection of Conbercept combined with 532-laser retinal photocoagulation for retinal vein occlusion. Guoji Yanke Zazhi( Int Eye Sci) 2017;17(2):284-287

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:September 06,2016
  • Revised:January 04,2017
  • Online: January 20,2017